pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

783 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT787Endpoints593BioPharma Dive228onclive165Fierce Biotech64BioSpace63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • <![CDATA[EGFR-Targeted Therapy Sequencing After Resistance in NSCLC]]>
    <![CDATA[Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[HERIZON-GEA-01 Study Design, Geographic Distribution, and PD-L1 Testing Considerations]]>
    <![CDATA[Experts debate PD‑L1 testing in HER2+ metastatic gastric cancer as new trial data reshapes when to add immunotherapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Integrating Evidence and Identifying Future Research Needs in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]>
    <![CDATA[Experts debate real-world evidence for prostate cancer drug comparisons, weighing trial limits, bias, and data that guides care.]]>
← prev
page 26 of 32
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago
↗ source
  • <![CDATA[Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEA]]>
    <![CDATA[Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Co-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy Response]]>
    <![CDATA[Learn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Evaluating Observational and Propensity Matched Studies in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]>
    <![CDATA[Experts weigh real‑world evidence for prostate cancer drug comparisons, explaining bias risks, data quality, and how it complements trials.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Reigniting Your Curiosity During Fellowship ]]>
    <![CDATA[Megan M. Dupuis, MD, PhD, discusses how oncology fellows can keep their personal and professional curiosities alive during fellowship.]]>
    onclive · 2mo ago↗ source
  • Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst
    Angelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases. The buyout will add three medicines to Angelini’s…
    Endpoints · 2mo ago↗ source
  • <![CDATA[MANEUVER Trial Underscores Potential Paradigm Shift Toward Targeted Approaches in TGCT ]]>
    <![CDATA[R. Lor Randall, MD, FACS, discusses how the introduction of systemic therapies like pimicotinib in TGCT enables a tumor biology–informed approach to care.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma]]>
    <![CDATA[Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer]]>
    <![CDATA[Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.]]>
    onclive · 2mo ago↗ source
  • Amgen, AbbVie say IRA negotiations impacted Q1 sales
    At least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug prices negotiated under the law took effect in January. Amgen and AbbVie reported in th…
    Endpoints · 2mo ago↗ source
  • <![CDATA[Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLC]]>
    <![CDATA[Jonathan Wennan Lee, MD, MSc, discusses future directions for studying PD-L1 as a predictive biomarker in EGFR-mutated NSCLC. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma]]>
    <![CDATA[Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.]]>
    onclive · 2mo ago↗ source
  • Lilly plans new $4.5B manufacturing investment in Indiana
    Eli Lilly is committing to its roots, allocating $4.5 billion for new manufacturing investments across Indiana as drugmakers pledge more US projects. The world’s largest pharma company, headquart…
    Endpoints · 2mo ago↗ source
  • BeOne culls five cancer programs and an autoimmune Phase 2
    BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the drugmaker will likely cull more experi…
    Endpoints · 2mo ago↗ source
  • Lonza looks to ride ADC wave with upcoming factory, workforce expansion
    BASEL, Switzerland — Lonza said it wants to own the commercial market for antibody-drug conjugates, with a new manufacturing site set to come online next year and plans to increase its headcount.…
    Endpoints · 2mo ago↗ source
  • <![CDATA[FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC]]>
    <![CDATA[An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma]]>
    <![CDATA[Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Sznol on Biomarkers of Response in Metastatic Melanoma]]>
    <![CDATA[Mario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery]]>
    <![CDATA[The State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research.]]>
    onclive · 2mo ago↗ source
  • Madrigal's Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts
    🚀 Madrigal Pharmaceuticals' MASH drug beats expectations: The biotech’s Rezdiffra sales came in at $311 million for the first quarter, surpassing analysts’ projections by about $10 million, accord…
    Endpoints · 2mo ago↗ source
  • Former Orbital scientists launch new mRNA therapy startup
    Two scientists think they've solved a technical problem that has kept the mRNA revolution from reaching its full potential. Now, they're launching ParcelBio with $13 million in seed funding to dev…
    Endpoints · 2mo ago↗ source
  • Avalo scores Phase 2 success in comeback bid, raises $375M
    Avalo Therapeutics’ comeback bid surged forward Tuesday afternoon, as the immunology biotech secured a mid-stage trial win in an inflammatory skin disorder. Avalo said that both doses of an exper…
    Endpoints · 2mo ago↗ source